Prevotella-Derived Butyrate Inhibits CD8+ T-Cell Glycolysis via AKT/mTOR Signalling to Alleviate MASH - PubMed
4 hours ago
- #MASH
- #CD8+ T cells
- #Prevotella
- Prevotella-derived butyrate inhibits CD8+ T-cell glycolysis via AKT/mTOR signaling to alleviate MASH.
- Prevotella abundance is significantly reduced in MASH patients compared to healthy controls.
- Oral administration of Prevotella alleviates hepatic lipid accumulation and collagen deposition in MASH mice.
- Prevotella suppresses glycolytic activity in CD8+ T cells by decreasing 2-NBDG uptake and ECAR measurements.
- Prevotella downregulates the PI3K/AKT/mTOR signaling pathway in CD8+ T cells.
- The combination of Prevotella with a glycolysis inhibitor does not enhance therapeutic efficacy beyond Prevotella alone.
- Prevotella mitigates MASH by downregulating the PI3K/AKT/mTOR-glycolysis axis in CD8+ T cells via butyrate-dependent mechanisms.